Merck & Co., Inc.  

(Public, NYSE:MRK)   Watch this stock  
Find more results for MRK
62.63
-0.31 (-0.49%)
Jul 21 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 62.58 - 63.00
52 week 57.18 - 66.80
Open 62.79
Vol / Avg. 6.91M/9.02M
Mkt cap 171.33B
P/E 40.12
Div/yield 0.47/3.00
EPS 1.56
Shares 2.74B
Beta 0.81
Inst. own 76%
Jul 28, 2017
Q2 2017 Merck & Co Inc Earnings Release - 9:30AM EDT - Add to calendar
Jul 28, 2017
Q2 2017 Merck & Co Inc Earnings Call - 8:00AM EDT - Add to calendar
Jun 13, 2017
Merck & Co Inc at Goldman Sachs Global Healthcare Conference - Webcast
Jun 5, 2017
Merck & Co Inc Investor Briefing at 2017 ASCO Annual Meeting
Jun 2, 2017
Merck & Co Inc at Sanford C Bernstein Strategic Decision Conference - Webcast
May 23, 2017
Merck & Co Inc Annual Shareholders Meeting - Webcast
May 4, 2017
Merck & Co Inc at Deutsche Bank Health Care Conference - Webcast
May 2, 2017
Q1 2017 Merck & Co Inc Earnings Release
May 2, 2017
Q1 2017 Merck & Co Inc Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '17) 2016
Net profit margin 16.49% 9.90%
Operating margin 21.85% 12.24%
EBITD margin - 58.35%
Return on average assets 6.50% 4.00%
Return on average equity 15.57% 9.25%
Employees 68,000 -
CDP Score - B

Address

2000 Galloping Hill Rd
KENILWORTH, NJ 07033-1310
United States - Map
+1-908-7404000 (Phone)
+1-908-4231987 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
About Company - Wikipedia

Description

Merck & Co., Inc. is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company's Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed healthcare providers, such as health maintenance organizations, pharmacy benefit managers and other institutions. Vaccine products consist of preventive pediatric, adolescent and adult vaccines, primarily administered at physician offices.

Officers and directors

Kenneth C. Frazier Chairman of the Board, President, Chief Executive Officer
Age: 62
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Robert M. Davis Chief Financial Officer, Executive Vice President
Age: 50
Bio & Compensation  - Reuters
Michael J. Holston Executive Vice President, General Counsel
Age: 54
Bio & Compensation  - Reuters
Mirian M. Graddick-Weir Executive Vice President - Human Resources
Age: 62
Bio & Compensation  - Reuters
Sanat Chattopadhyay Executive Vice President and President - Merck Manufacturing Division
Age: 57
Bio & Compensation  - Reuters
Richard R. DeLuca Jr. Executive Vice President, President - Merck Animal Health
Age: 54
Bio & Compensation  - Reuters
Julie Louise Gerberding M.D. Executive Vice President and Chief Patient Officer, Strategic Communications, Global Public Policy and Population Health
Age: 61
Bio & Compensation  - Reuters
Roger M. Perlmutter M.D. Ph.D. Executive Vice President, President - Merck Research Laboratories
Age: 65
Bio & Compensation  - Reuters
Adam H. Schechter Executive Vice President, President - Global Human Health
Age: 52
Bio & Compensation  - Reuters
Rita A. Karachun Senior Vice President Finance - Global Controller
Age: 53
Bio & Compensation  - Reuters